Navigation Links
Astellas Expands Leadership Team With Senior Vice President of Corporate Strategy and Government Affairs
Date:8/15/2011

DEERFIELD, Ill., Aug. 15, 2011 /PRNewswire/ -- Astellas US, LLC ("Astellas") recently named Percival Barretto-Ko as Senior Vice President, Corporate Strategy and Government Affairs, a new position added to the company's leadership team.  Reporting to President and CEO Masao Yoshida, Barretto-Ko will be responsible for corporate planning, business development, government policy and external affairs and state government affairs.

"This realignment brings key strategic functions closer together at the corporate level," Yoshida said.  "Percival has an outstanding track record both in the pharmaceutical industry and at Astellas' European operations.  He will be a great addition to our senior management team."

Barretto-Ko will move from the position of executive director, corporate strategy and communications at Astellas Pharma Europe Ltd.  While there, he led the global launch of Astellas' new pipeline drug, Advagraf® (tacrolimus prolonged release) in 20 countries. He was promoted to lead the organization's corporate planning function and ultimately directed corporate strategy, corporate planning, corporate communications, crisis management and corporate social responsibility. Prior to joining Astellas, he held increasingly more senior marketing and sales positions with the Roche Group in the United States and United Kingdom. Barretto-Ko earned his undergraduate degree from Cornell University, an MBA from Yale School of Management, and an MS from MIT Sloan School of Management, where he recently served as a Sloan Fellow for Innovation and Global Leadership.

About Astellas

Astellas US LLC, located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas US LLC, please visit our website at www.astellas.us or follow us on Twitter at www.Twitter.com/AstellasUS.


'/>"/>
SOURCE Astellas US, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise
2. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
3. Astellas to Review Strategic Business Alternatives for Prosidion Subsidiary
4. Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile
5. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
6. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
7. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
10. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
11. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... July 10, 2017 Locus Biosciences Inc. today ... support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for ... leading Chinese Internet services provider, and joined by the ... infectious disease product programs targeting antibiotic resistant infections and ... Founded by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), today announced that it has reached ... holder and largest shareholder, to modify its existing credit ... to the modification, WAVI agreed to exchange its existing ...
(Date:6/27/2017)... TEL AVIV, Israel , June 27, 2017 /PRNewswire/ ... a specialty clinical-stage pharmaceutical company specializing in the development ... ring The Nasdaq Stock Market Opening Bell in ... 28, 2017 in honor of its initial public offering ... Nasdaq Capital Market in March 2017. Dr. ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed ... . The number of hospital acquisitions rose to 23 in the second quarter, up ... up 15% from the 20 announced deals in the year-ago second quarter. Only four ...
(Date:7/21/2017)... NJ (PRWEB) , ... July 21, 2017 , ... ... has received a $5,000 grant from the C. R. Bard Foundation, ... Day Center at Somerset Hills , a service available through the nonprofit home ...
(Date:7/21/2017)... ... , ... West Dermatology is pleased to announce the newest addition to their ... Vu will join West Dermatology’s large network of medical and cosmetic dermatology practices, bringing ... and more. She graduated from the University of Florida College of Medicine Physician Assistant ...
(Date:7/20/2017)... ... , ... TransPixel Volume 2 is a set of transitions that create a ... isolates horizontal and vertical lines of pixels and sorts their pixels by darkness, brightness, ... and can be changed using a drop-down menu. Create amazing and artistic transitions using ...
(Date:7/20/2017)... ... July 20, 2017 , ... Coats Rose, P.C. , ... announce their expansion to the Midwest with the establishment of the firm’s new ... Bell, and of counsels, John Peck and Robert Bruns, will establish and anchor ...
Breaking Medicine News(10 mins):